WTA’s SRY gene test reshapes tennis eligibility rules

The WTA’s new SRY test: what it is, why it matters, and the messy road ahead

Big change in women’s tennis: the WTA has announced a one-time mandatory genetic sex test for every player on tour. It’s a short sentence that rewrites a lot of assumptions about who gets to play, and that’s why this is suddenly everywhere — not just on tennis feeds, but in conversations about sport, law and rights. The tour says the test looks for the SRY gene; the reaction has been immediate and loud. ESPN reported the new rule as part of an updated eligibility framework, and the BBC has laid out how it replaces the previous testosterone-based approach. BBC

What exactly did the WTA change?

The headline is simple: players must provide a biological sample — a cheek swab, blood or saliva — for a one-time genetic screen that detects the SRY gene. That gene is typically found on the Y chromosome and is associated with male sex development.

The policy says a negative test is required to compete on the women’s tour. If someone tests positive for SRY, the WTA says there will be further medical assessment before any eligibility decision is made. The tour has framed this as an update to its women’s eligibility rules “based on biological sex.” ESPN

What it replaces

Before this, the WTA ran a model based on testosterone. The old framework allowed transgender women to compete provided their testosterone was below 2.5 nmol/L continuously for two years — a rule the BBC reports the tour has now abandoned in favour of genetic screening. BBC

How the test works (and what it looks for)

There’s a lot of scientific shorthand being thrown around, so it helps to be clear about the narrow thing the tests are actually checking.

The sample types are straightforward: cheek swab, blood or saliva.
The laboratory look is for the SRY gene — commonly present on the Y chromosome and linked to male sex development.
The test is one-time only in a player’s lifetime, according to the policy.

If the SRY gene is not detected, a player is cleared to compete. If it is detected, the WTA says there will be additional medical assessment before any final eligibility decision is made. The policy also requires players to sign an acknowledgement that refusing the test could result in disciplinary action. BBC

Why this matters for tennis — and for Los Angeles 2028

This isn’t just an internal housekeeping fix. The WTA itself and outside commentators have framed the move as having wider implications, including Olympic considerations.

The WTA says the changes are about preserving fair competition by clarifying eligibility “based on biological sex.” It’s also been reported that the update brings the tour more in line with the International Olympic Committee’s eligibility policy issued in March, and that it’s partly driven by the environment around the 2028 Los Angeles Games. ESPN

Put bluntly: who is allowed on the women’s draw matters not just for Grand Slams and rankings, but for who might wear their country’s colours at the Olympics. That raises stakes for federations, national selectors and the players themselves.

Reactions: why it’s become a major off-court story

This has already turned into one of those headline-grabbing off-court stories that sit at the intersection of sports policy, identity and rights.

The shift from a testosterone threshold to a genetic screen is a big conceptual leap, and that’s why commentators are calling it a major gender-eligibility story in women’s sport. ESPN
Human rights experts and activist groups have criticised the approach, arguing it raises questions about dignity, privacy and discrimination — according to reporting on the rollout. ESPN
The WTA has stated there is “no intent to disrespect or question the gender identity or the dignity of any person,” but the policy explicitly distinguishes biological sex from gender identity, which is where much of the pushback is focused.

All of that means this isn’t going to be a quiet administrative change. Expect legal, ethical and public debates, especially where national laws and human-rights frameworks differ.

Practical fallout that could happen

We don’t know who, if anyone, will immediately be affected, but the policy could trigger a few real-world scenarios:

Players being asked to provide samples and then entering an additional medical review process.
Disciplinary procedures if someone refuses to comply with the test requirement — that’s expressly in the policy. BBC
Pressure on national federations and Olympic selectors to reconcile differing rules between bodies.

What we still don’t know (and why that matters)

The reporting so far leaves significant gaps — and those gaps are the reason debates will be messy and prolonged.

We don’t have numbers on how many players have taken the test yet, or how many will refuse.
There are no named players publicly affected at the time of these reports.
The rollout details — timelines, data governance, how results are stored, who has access — haven’t been published in full in the pieces that broke the news.

Those are practical questions that matter for privacy and for how quickly this policy actually changes entries and draws. Right now it’s a policy on paper with a high potential to change how things play out on the court in the future.

What people inside and outside tennis are likely thinking

Players and coaches will be weighing the practicalities: Is this a quick cheek swab and done, or the start of a process that will drag on? National bodies will be parsing whether this aligns with their own rules. Activists and rights groups will be looking at legal avenues and public messaging.

The WTA is threading a needle: it’s trying to say the aim is preserving fair competition while also noting there’s no intent to disrespect gender identity. That will be hard for some to accept because the policy itself rests on a biological/identity distinction.

A short reality check

For fans who love the on-court stuff, this is worth tracking because eligibility rules have real effects: who plays who, who gets into slams, and who represents their country. But don’t expect immediate line-ups to change overnight — not without more operational detail and probably some legal sparring.

FAQ — common questions fans are actually asking

Q: Who has to take this test?

A: According to the WTA policy reporting, all players on the women’s tour must provide a sample — cheek swab, blood or saliva — for the one-time SRY genetic screen. ESPN

Q: What happens if a player tests positive for SRY?

A: The WTA says a positive test leads to further medical assessment before any eligibility decision is finalised. The policy doesn’t say that a positive test equals immediate disqualification. BBC

Q: Is this aimed specifically at transgender women?

A: The WTA frames the rule as based on biological sex and has moved away from a testosterone threshold model. The tour has said there is no intent to disrespect gender identity, but the policy’s focus on genetics rather than hormone levels has led many to see it as directly relevant to transgender eligibility. ESPN

Q: How is this different from the old testosterone rule?

A: Previously, the WTA allowed transgender women to compete if their testosterone stayed below 2.5 nmol/L for two years. The new approach swaps that hormonal threshold for a genetic screen looking for the SRY gene. BBC

Q: Could this affect who goes to the Olympics?

A: Yes. Reporters have linked the change to the WTA aligning more with the IOC’s eligibility policy and concerns around Los Angeles 2028, so Olympic implications are part of why this matters. ESPN

Q: Are there legal or human-rights challenges likely?

A: Human rights experts and activist groups have already criticised the approach, and with the policy touching on identity and medical data, legal challenges or formal complaints seem likely. The reports don’t detail any specific legal filings yet. ESPN

Where this leaves the sport

Here’s the blunt summary you can take to a pub or a park bench and not get yelled at: the WTA has shifted from a hormone-based eligibility test to a one-time genetic screen. That’s a structural change, not a tweak.

It’s a policy that promises clarity for those who want a clear biological line, but it also raises huge ethical and privacy questions that the reporting so far does not answer. Right now, the WTA’s move has created more questions than answers about rollout, enforcement and real-world consequences.

What will decide how big this becomes is partly practical: how many players are affected, how many refuse, and how national bodies and the IOC respond. But it’s also political and legal. Expect this to be litigated in the public sphere as much as in the courts.

One last practical note for fans who gamble or follow odds casually: this policy isn’t about match odds or rankings directly, but eligibility rules can influence who plays. If you look at markets, remember they can shift if a player’s ability to enter events changes — and if you’re betting, be responsible about it.

Conclusion

The simple thing to remember: the WTA has replaced a testosterone-based eligibility rule with a one-time genetic (SRY) test for all women’s tour players, a change that raises sporting, Olympic and human-rights questions. How big the impact will be depends on details we don’t yet have — and on how players, federations and rights groups respond.